Navigation Links
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Date:5/21/2013

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 – 4:30 PM.  The presentation will describe the results of a first-in-human study of MacroGenics' next-generation anti-HER2 monoclonal antibody, margetuximab, which is being developed to treat HER2-expressing tumors.  

MacroGenics has optimized the Fc region of margetuximab to increase cancer cell killing via Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).  Margetuximab also has shown improved control of tumor growth in human tumor xenograft models in mice as compared to that of anti-HER2 antibodies with a wild type Fc region.  A development goal for margetuximab is to enable the treatment of a broader population of patients than those eligible for treatment with current HER2-targeted therapies.

MacroGenics also announced that the first patient has received study drug in a Phase 2 clinical study evaluating margetuximab in patients with metastatic breast cancer.  This study is designed to evaluate the activity of margetuximab in up to 41 patients with metastatic breast cancer whose tumors express a moderate level of the oncoprotein, HER2, represented by a 2+ score by immunohistochemistry.  These tumors must also lack evidence of HER2 gene amplification as determined by FISH testing.  The trial is being conducted at six sites across the United States.  For more information on the clinical trial, please see www.clinicaltrials.gov.

"To date, the results of our Phase 1 s
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
2. Revolutionary Science Announces New Automatic and Manual Colony Counting Products
3. Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing
4. SoundConnect Announces Microsoft Lync Release in Canada
5. GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit
6. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
7. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
8. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
9. DNA Genotek Inc. Announces Spit for Africa Program
10. Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
11. Discovery Labs Announces Completion of $14.25 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... -- Intrexon Corporation (NYSE: XON ), a leader ... previously announced public offering of common stock, including the ... to purchase an additional 731,707 shares of common stock ...  The exercise of the underwriters, option brought the total ... to 5,609,756 shares and increased the total gross proceeds ...
(Date:8/26/2015)... Aug. 26, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has been informed ... entity wholly owned by Mr. Yuen Kam, chairman of ... the outstanding shares (the "Shares") of  Excellent China Healthcare ...
(Date:8/26/2015)... , August 26, 2015 ... biggest factors fueling the optimism in biotech,s forecast ... collaborations and life sciences advancements.  Active biotechnology & ... Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: ... SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: RPTP ...
(Date:8/26/2015)... , ... August 26, 2015 , ... The 2015 Epigenomics ... adult stem cell technology start-up company Asymmetrex to share the first report ... of a new biomarker for counting adult tissue stem cells. , With a name ...
Breaking Biology Technology:Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... DIEGO, June 4 Anadys Pharmaceuticals, Inc. (Nasdaq: ... operations on the development of ANA598, in particular a proposed ... combination with pegylated interferon-alpha and ribavirin. , ... suspend further development of ANA773 and is reducing its workforce ...
... Push of a Button , , CLEVELAND, June 4 ... the patented probiotic strain Ganeden BC30 (R), today announced a ... beverage using PowerCap(R) technology, the innovative bottle cap dispensing system. ... with the press of a button, creating a new category ...
... Roche at 69th Scientific Sessions , , SAN ... VIAP ), a biotechnology company focused on the ... metabolic disease, announced today that preclinical data related to ... presented in a poster presentation at the 69th Scientific ...
Cached Biology Technology:Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 2Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 3Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 4Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 5Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology 2Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/12/2015)...  New research unveiled at Black Hat 2015 ... steal users, fingerprints. Information released today by HYPR ... on mobile devices, making the security of this ... mobile devices, HYPR Corp. recently released a biometric ... with strong cryptographic security. More information on this ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... One delivers new insight about rapid toxin evolution in ... an arms race with opossums, a group of snake-eating American ... venomous snakes, this fact has not been factored into previous ... venom is usually seen as a feeding, or trophic, adaptation. ...
... Researchers from the John Theurer Cancer Center at ... studies during the recently concluded American Society of Clinical ... 7, 2011 in Chicago. The studies examined new ... and patient quality of life issues. "ASCO ...
... countries Thursday in a recommendation to regional fishery management ... unreported and unregulated (IUU) fishing for tunas, swordfish, sharks ... due to IUU fishing are estimated to be as ... first step toward procedures for sharing information about vessels ...
Cached Biology News:Rapid venom evolution in pit vipers may be defensive 2Rapid venom evolution in pit vipers may be defensive 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 2John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 4John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 5John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 6US joins over 50 nations in adopting recommendation to list vessels engaged in illegal fishing 2US joins over 50 nations in adopting recommendation to list vessels engaged in illegal fishing 3
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
... H- Reverse Transcriptase (RT) is an improved ... It is a DNA polymerase that synthesizes ... DNA or an RNA:DNA hybrid. This enzyme ... point mutations rather than a deletion in ...
... Reverse Transcriptase (RT) is an improved version ... is a DNA polymerase that synthesizes a ... or an RNA:DNA hybrid. This enzyme is ... mutations rather than a deletion in the ...
... Polynucleotide Kinase (PNK) catalyzes the transfer ... the 5'-hydroxyl of single- and double-stranded ... enzyme also removes the 3'-phosphate from ... 3', 5'-diphosphates to form a 3'-hydroxyl ...
Biology Products: